UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 7, 2019

Sarepta Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Delaware	001-14895	93-0797222
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

215 First Street
Suite 415
Cambridge, MA 02142
(Address of principal executive offices, including zip code)

(617) 274-4000
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 7, 2019, Douglas S. Ingram, President and Chief Executive Officer of Sarepta Therapeutics, Inc. (the "Company") disclosed certain preliminary financial information for the year ended December 31, 2018 during the Company's presentation at the 37th Annual J.P. Morgan Healthcare Conference (the "Conference") and in discussions with third parties at the Conference. Specifically, the Company disclosed its cash position of $1.1 billion as of December 31, 2018 and that the Company generated approximately $84.4 million in revenue (unaudited) in the fourth quarter ended December 31, 2018, and approximately $301 million in revenue (unaudited) in the year ended December 31, 2018 from sales of EXONDYS 51® (eteplirsen) Injection. A copy of the slide presentation associated with this announcement is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02 is unaudited and preliminary, and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2018 and its results of operations for the three months and year ended December 31, 2018. The audit of the Company's financial statements for the year ended December 31, 2018 is ongoing and could result in changes to the information in this Item 2.02.

Item 7.01 Regulation FD Disclosure.

The disclosure in Item 2.02 above is hereby incorporated by reference into this Item 7.01.

The slides presented by Mr. Ingram at the Conference on January 7, 2019 are furnished with this report as Exhibit 99.1, which is incorporated herein by reference.

The information in this report and Exhibit 99.1 to this report is furnished pursuant to Items 2.02 and 7.01 and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Items 2.02 and 7.01 of this report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Sarepta Therapeutics, Inc. Presentation at the 37th Annual J.P. Morgan Healthcare Conference, dated January 7, 2019.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Sarepta Therapeutics, Inc.

By: /s/ Douglas S. Ingram
Douglas S. Ingram
President and Chief Executive Officer

Date: January 7, 2019

SAR
THER

37th Annual J.P. Morgan Healthcare Conference, San Francisco, CA, January

FORWARD LOOKING STATEMENTS

This presentation contains "forward-looking statements" within the meaning of the safe harbor provis
facts or words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible," “g
forward-looking statements. Forward-looking statements in this presentation include but are not limited to: Sa
benefits of MHCK7, AAVrh74, SR2 and SR3; the expectation to commercialize golodirsen in 2019 and to hav
plan to take scientific advise with EMA in connection with eteplirsen; our intention to play a central role in tra
therapy; our goal to build a gene therapy engine; our expected path forward in connection with our micro-dys
play a central role in that upending; the potential of gene therapy to have a higher probability of success from
years than all of the gene therapy manufacturing supply that exists in the world today; the estimated number
medicine pipeline in the world; our goal to continue to build our pipeline out and to have 40 programs; the po
covered by our programs; our milestones and expected timelines, including a target approval for golodirsen i
confirmatory trial for our micro-dystrophin program later in 2019, having results in LGMD in Q1 2019, dosing
Q1 2019; and other statements made during the presentation regarding Sarepta’s future, strategy and busine

These forward-looking statements involve risks and uncertainties, many of which are beyond Sarept
business. Actual results and financial condition could materially differ from those stated or implied by these fo
adversely affect Sarepta’s business, results of operations and trading price. Potential known risk factors inclu
2018 is ongoing and could result in changes to the information; we may not be able to meet expectations wit
to comply with all FDA post-approval commitments/requirements with respect to EXONDYS 51 in a timely m
the U.S., including from the EMA; our data for golodirsen, casimersen and/or our micro-dystrophin program m
strategic partners, may not result in viable treatments suitable for commercialization due to a variety of reaso
meet regulatory approval requirements for the safety and efficacy of product candidates; success in preclinic
later clinical trials will be successful; if the actual number of patients suffering from DMD, LGMD, and/or CMT
our dependence on our manufacturers to fulfill our needs for our clinical trials and commercial supply, includi
capacity to meet product demand, may impair the availability of products to successfully support various prog
product candidates; we may not be able to successfully scale up manufacturing of our product candidates in
business plans and goals, including meeting our expected or planned regulatory milestones and timelines, cl
possible limitations of our financial and other resources, manufacturing limitations that may not be anticipate
may not be positive, and regulatory, court or agency decisions, such as decisions by the United States Pater
Annual Report on Form 10-K or and most recent Quarterly Report on Form 10-Q filed with the Securities and

For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review Sa
forward-looking statements contained in this presentation. The forward-looking statements in this presentatio
Sarepta does not undertake any obligation to publicly update its forward-looking statements.

OUR GOALS FOR 2018

- Build out our pipeline
- Ensure we have the resources to build for the fu
- Clarify a pathway for our RNA technology
- Become one of the most important rare disease companies
- Have another strong year of commercial execution

EXPANSION OF OUR RNA AND GENE T

2

PROG



RNA

Gene Therapy/Editing

*Candidate received accelerated approval in the U.S., confirmatory studies required

**Other exon targets in development: 43, 44, 50 and 55

RESOURCES AND TALENT*

*As of December 31, 2018; preliminary and unaudited results

DEFINED RNA PATHWAY

If success
by 2020,
commun

2016

2(

EXONDYS 51™
(eteplirsen) Injection

GOLO

EXECUTION

2016
LAUNCH

FY'17
$154.6M

EXONDYS 51™
(eteplirsen) Injection

*Preliminary and unaudited results

TOP 5 RARE DISEASE COMPANIES*

*By Market Cap

We are S

MICRO-DYSTROPHIN PROGRAM OVE

- **AAVrh74** provides broad distribution to **all** m
- **SR2** and **SR3** critical for force production
- **MHCK7** promoter enables robust dystrophin



ITR, inverted tandem repeat; SR, spectral-like repeat.

UNPRECEDENTED EARLY STA
RESULTS*

81%

Robust expression of micro-dystrophin in muscle fibers

96%

Robust expression of micro-dystrophin measured by Western blot** and signal intensity

Reduction of creatine kinase

78%

Improvements across all measured functions***

Well-tolerated

* Data from the 4 patients dosed in Study NCT03375164
**NCH Western blot method
***North Star Ambulatory Assessment (NSAA), Time to Rise, 4 Stairs Up, and 100M

THE PATH FORWARD



And our intent is to do t

7,000 Rare Diseases

~80% are single gene mutations

- And Only 1 FDA Approved GENE THERAPY

15 y

GENE THERAPY CAN UPEND THIS MODEL

AND WE WILL PLAY A ROLE IN UPENDING THE MODEL

PROBABILITY OF SUCCESS

TIMELINES

MASSIVE OPPORTUNITY TO DO GOOD

PROBABILITY OF SUCCESS

WE DON’T RELY O

WE ENGINEE


OUR
MANUFACTURING
STRATEGY
The largest gene therapy capacity around the globe

- Duchenne Muscular Dystrophy
- Limb-girdle Muscular Dystrophy
- Charcot-Marie-Tooth Disease
- Mucopolysaccharidosis
- Pompe Disease

MASSIVE OPPORTUNITY TO DO GOOD

THE MOST ROBUST PRECISION

*Based on published epidemiology


We are upend

Because some


PULL
TOMO
INT
TOD


SARE
THERAPEU